^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CTLA4 expression

    i
    Other names: CTLA4, Cytotoxic T-Lymphocyte Associated Protein 4, Insulin-Dependent Diabetes Mellitus 12, Cytotoxic T-Lymphocyte Protein 4, Celiac Disease 3, CTLA-4, CD152, Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4, Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form, Cytotoxic T-Lymphocyte-Associated Serine Esterase-4, Cytotoxic T-Lymphocyte-Associated Antigen 4, CD152 Isoform, CD152 Antigen, CELIAC3, IDDM12, ALPS5, GRD4
    Entrez ID:
    1493
    Related biomarkers:
    Expression
    Mutation
    Others
    1d
    The diversity of inhibitory receptor co-expression patterns of exhausted CD8+ T cells in oropharyngeal carcinoma. (PubMed, iScience)
    In OPSCC patients, programmed cell death-1 (PD-1) blockade significantly enhanced PDCD1-based co-expression with other IR genes, whereas dual blockades of PD-1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) significantly upregulated CTLA4-based co-expression with other IR genes. Collectively, our findings demonstrate that highly diverse IR co-expression is a leading feature of Texs and represents their functional states, which might provide essential clues for the rational selection of immune checkpoint inhibitors in treating OPSCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    CTLA4 expression
    7d
    VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma. (PubMed, Front Oncol)
    This correlation may refer to the role of VISTA as a receptor in the TCs and not in the immune cells. Thus, targeting combination therapy blocking VISTA, CTLA4, and PD1 could be a novel and attractive strategy for HGSOC treatment, considering the ambivalent role of VISTA in the HGSOC tumor cells.
    Journal • PD(L)-1 Biomarker • IO biomarker • Tumor cell
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • VSIR (V-Set Immunoregulatory Receptor)
    |
    PD-L1 expression • PD-1 expression • CTLA4 expression
    11d
    Verification of the expression trend and interaction prediction of innate immune cells and immune-checkpoint molecules in the process of oral mucosal carcinogenesis. (PubMed, Hua Xi Kou Qiang Yi Xue Za Zhi)
    Therefore, interference with specific immune cells in innate immunity can regulate the expression of CTLA4 and/or PD-L1 to a certain extent, inhibit tumor immune escape, and delay the progression of oral mucosal carcinogenesis.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • CTLA4 expression • PD-L1 expression + CTLA4 expression
    12d
    Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status (PubMed, Arkh Patol)
    A study using multiplex immunohistochemical analysis showed that MMR-deficient colon adenocarcinomas are characterized by more pronounced immune infiltration and increased expression of immune checkpoints in microenvironmental cells, mainly in the area of invasive tumor growth. The data obtained may be important for understanding the mechanisms of immune-mediated control of tumor growth and the choice of immunotherapy tactics depending on MMR status.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • MLH1 (MutL homolog 1) • LAG3 (Lymphocyte Activating 3) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • CD163 (CD163 Molecule)
    |
    PD-L1 expression • MSI-H/dMMR • LAG3 expression • CTLA4 expression
    12d
    Identification of Two Distinct Immune Subtypes in Hepatitis B Virus (HBV)-Associated Hepatocellular Carcinoma (HCC). (PubMed, Cancers (Basel))
    This study identifies two distinctive immune subtypes in HBV-associated HCC, regardless of the microenvironment observed in the surrounding nontumorous tissue, providing new insights into pathogenesis. These findings may be instrumental in the identification of patients who might benefit from immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    CTNNB1 mutation • CTLA4 expression
    14d
    Single-cell data revealed exhaustion of characteristic NK cell subpopulations and T cell subpopulations in hepatocellular carcinoma. (PubMed, Aging (Albany NY))
    CTLA4+ T cell subsets in HCC exhibited functional exhaustion characteristics that probably inhibited T cell function through a transcription factor network dominated by NR3C1, STAT1, and STAT3.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    |
    CTLA4 expression
    16d
    CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer. (PubMed, Am J Cancer Res)
    In this study, we analyzed sera obtained from advanced gastric cancer patients before and one month after treatment with anti-PD1 nivolumab for soluble IC molecules by ELISA...However, treatment with anti-CTLA4 mAb or a PPARγ agonist that can reduce in vivo CRP successfully elicited anti-tumor efficacy in the anti-PD1 resistant models. These suggest that targeting CRP and sCTLA4 may be a promising strategy for improving clinical outcomes in the treatments, including anti-PD1 therapy, of GI cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    CTLA4 expression
    |
    Opdivo (nivolumab)
    18d
    Immunomodulation by juglone alleviates acute graft-versus-host disease without compromising the graft-versus-leukaemia activity in mice. (PubMed, Br J Pharmacol)
    Juglone is a potent immunomodulator for GVHD prophylaxis. Our study is the first to provide a dosage framework for the oral administration of juglone that can be used for clinical development.
    Preclinical • Journal • IO biomarker • Immunomodulating
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FAS (Fas cell surface death receptor)
    |
    CTLA4 expression
    19d
    Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail. (PubMed, NPJ Precis Oncol)
    Differences in IO-related gene expression and TIME cell distribution suggest that response to IO therapies may differ in PDAC arising from H vs. B/T. Subtle differences in the genomic profiles of H vs. B/T tumors were observed.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • PD-1 (Programmed cell death 1) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • FGF3 (Fibroblast growth factor 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • FGF4 (Fibroblast growth factor 4) • IDO1 (Indoleamine 2,3-dioxygenase 1) • FLT4 (Fms-related tyrosine kinase 4) • MUTYH (MutY homolog) • ZNF703 (Zinc Finger Protein 703)
    |
    KRAS mutation • IDO1 expression • CTLA4 expression
    |
    MI Tumor Seek™
    20d
    Prognostic and Immune Landscape Analysis of Ubiquitination-related Genes in Hepatocellular Carcinoma: Based on Bulk and Single-cell RNA Sequencing Data. (PubMed, J Cancer)
    Furthermore, single-cell data analysis revealed heterogeneous expression of hub UbRGs across different cell subtypes, while cytological experiments provided additional confirmation of the high expression of hub UbRGs in HCC. Our study provides valuable insights into the identification of novel ubiquitination-related biomarkers with potential applications for prognosis, immunotherapy prediction, and drug sensitivity in HCC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • BOP1 (BOP1 Ribosomal Biogenesis Factor) • CDC20 (Cell Division Cycle 20)
    |
    PD-1 expression • CTLA4 expression
    25d
    Role of CD38 in anti-tumor immunity of small cell lung cancer. (PubMed, Front Immunol)
    A combination of cisplatin/etoposide, ICB, and CD38 blockade delayed tumor growth compared to cisplatin/etoposide. Our study provides a preliminary but important direction toward exploring CD38 as a potential biomarker of ICB response and CD38 blockade as a combination strategy for chemo-immunotherapy in SCLC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • TMB-H • CD38 expression • CTLA4 expression • PD-L1-L • FOXP3 expression
    |
    cisplatin • etoposide IV
    27d
    Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. (PubMed, Cancer Immunol Res)
    Clinical responders possessed lower circulating frequencies of Ki67+ T and myeloid cells at baseline and higher circulating frequencies of TIM-3+ T and myeloid cells by week 9. Although R223+P did not induce T-cell infiltration into the tumor microenvironment, exhaustion of induced peripheral T-cell immune responses may dampen the combination's clinical activity.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
    |
    CTLA4 expression
    |
    Keytruda (pembrolizumab) • Xofigo (radium Ra-223 dichloride)
    29d
    Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. (PubMed, J Immunother Cancer)
    Our proteomic analysis reveals an intra-tumoral population of SMA+CAFs enriched in pure DM. Additionally, increased expressions of immune checkpoints (LAG-3 and PD-1) in LA and within tumor were associated with poorer prognosis. These findings might have therapeutic implications and help guide treatment selection in addition to informing potential prognostic significance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD163 (CD163 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • CD68 (CD68 Molecule)
    |
    LAG3 expression • CTLA4 expression
    29d
    B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia. (PubMed, Curr Issues Mol Biol)
    In our cohort, the patients with CLL expressed elevated levels of PD-1 and CTLA-4 immune checkpoints on activated and memory B cell subsets. However, there was no correlation between these immune checkpoint expressions and B2M levels.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • B2M (Beta-2-microglobulin) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-1 expression • CTLA4 expression • PD-1 elevation
    1m
    Multi-omics comprehensive analysis reveals the predictive value of N6-methyladenosine- related genes in prognosis and immune escape of bladder cancer. (PubMed, Cancer Biomark)
    Finally, the experimental verification shows that the m6A related genes, such as IGFBP1, plays an important role in the growth and metastasis of bladder cancer. These findings revealed the important roles of m6A MRGs in predicting prognosis, TMB status, TP53 mutation, immune functions and immunotherapeutic response in BC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IGFBP1 (Insulin Like Growth Factor Binding Protein 1)
    |
    TP53 mutation • PD-L1 overexpression • TMB-L • CTLA4 expression
    1m
    Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype. (PubMed, Front Oncol)
    Our results demonstrate that HNSCC patients' response to immune checkpoint inhibition shows a distinct immune signature in peripheral blood, which could help identify refractory patients earlier. Furthermore, strategies to overcome primary therapy failure by inducing a beneficial T cell phenotype or adding alternative immune checkpoint inhibitors could improve response rates and survival of HNSCC patients.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule)
    |
    CTLA4 expression
    1m
    Genomic and immune microenvironment features influencing chemoimmunotherapy response in gastric cancer with peritoneal metastasis: a retrospective cohort study. (PubMed, Int J Surg)
    This exploratory study comprehensively evaluated clinicopathological, genomic, and immune features and developed a novel prediction model, providing a rational basis for the selection of GC patients with PM for chemoimmunotherapy-involved conversion therapy.
    Retrospective data • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • CD8 (cluster of differentiation 8) • CDH1 (Cadherin 1) • CD4 (CD4 Molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    HER-2 mutation • CD8 expression • ERBB3 mutation • CDH1 expression • CDH1 mutation • CTLA4 expression
    1m
    Fibroblast activation protein promotes progression of hepatocellular carcinoma via regulating the immunity. (PubMed, Cell Biol Int)
    The FAP overexpression promoted proliferation and migration while inhibiting the apoptosis of HCC cells. The FAP overexpression promoted the progression of HCC by regulating the immunity to affect the prognosis of HCC patients, thereby serving as a poor prognostic marker for HCC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FAP (Fibroblast activation protein, alpha) • ANXA5 (Annexin A5)
    |
    PD-L1 overexpression • PD-1 expression • CTLA4 expression • FAP expression • FAP overexpression
    1m
    Assessment of CTLA-4 Gene Expression Levels on CD8+ T Cells in Renal Transplant Patients and Relation with Serum sCTLA-4 Levels. (PubMed, Biochem Genet)
    Several parameters should be evaluated together to precise rejection episodes or graft dysfunctions. Further research focused on the other immune checkpoint regulator molecules could give an opportunity to have an idea about the effect of these molecules on renal transplantation.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
    |
    CD8 expression • CTLA4 expression
    2ms
    CTLA-4 Blockade of Natural Killer Cells Increases Cytotoxicity against Acute Lymphoid Leukaemia Cells Neda. (PubMed, Cell J)
    Our findings suggest that CTLA-4 blockage of Nalm-6 cells causes an increase in antitumour activity of NK cells against these cells. Our study also provides evidence for the potential of cancer immunotherapy treatment using blocking anti-CTLA-4 mAbs.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • GZMB (Granzyme B) • IL15 (Interleukin 15) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    CTLA4 expression • CTLA4 underexpression
    2ms
    Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade. (PubMed, Sci Rep)
    Combination PD-1 and IL-10 blockade signficantly increased cell death in human FLC TSCs. Immunosuppresion in the FLC tumor microenvironment is characterized by T cell exclusion and exhaustion, which may be reversible with combination immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL10 (Interleukin 10) • CASP3 (Caspase 3)
    |
    PD-1 expression • CTLA4 expression
    2ms
    Describing the molecular landscape of cervical cancer metastases: Implications for future therapeutic targets (AACR 2024)
    Hierarchical clustering of CCM sites by alterations (mutations, amplifications and fusions) frequency revealed CCM to Liver (n=77) and Lymph Nodes (n=265) as the most distinct from CCP while Vagina/Vulva (V/V) (n=196) and Lung (n=115) CCM were most similar. Lymph Nodes had decreased TP53-mt (6.6% vs 14.7%) and ARID1A-mt (4.53% vs 8.27%) but higher BRCA1-mt (3.03% vs 0.87%) compared to CCP (p<0.05). Liver had higher BRCA1-mt (6.67% vs 0.87%), ASXL1-mt (8.47% vs 2.96%) and APC-mt (4% vs 0.65%) compared to CCP (p<0.05).
    Tumor mutational burden • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • ASXL1 (ASXL Transcriptional Regulator 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
    |
    CTLA4 expression
    |
    PD-L1 IHC 22C3 pharmDx • MI Tumor Seek™
    2ms
    Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti-breast cancer immunity: An in vitro study. (PubMed, Scand J Immunol)
    The combination of FLLL32 and Herceptin suppress the expression of immune checkpoints and provoke the T-helper1 immune response in lymphocytes. Our analysis indicates STAT3 as a promising target that improves Herceptin's role in breast cancer cell apoptosis.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    HAVCR2 expression • CTLA4 expression
    |
    Herceptin (trastuzumab)
    2ms
    Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    CTLA4 expression
    |
    hydroxychloroquine
    2ms
    Molecular and serological biomarkers to predict trastuzumab responsiveness in HER-2 positive breast cancer. (PubMed, J Med Life)
    Co-targeting HER-2 and IGF-1 receptors may reduce the risk of recurrence and improve outcomes. In addition, targeted CTLA-4 molecules may improve patient survival and prevent recurrence.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • IGF1 (Insulin-like growth factor 1)
    |
    HER-2 positive • CTLA4 expression
    |
    Herceptin (trastuzumab)
    2ms
    An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer. (PubMed, Front Immunol)
    Patients with low expression of PDL1 or high expression of CTLA4 and low ERLS exhibited significantly better survival prospects, whereas patients with high ERLS and low levels of PDL1 or CTLA4 exhibited the poorest outcomes. Our study constructed an ERLS model that can predict prognostic risk and immunotherapy response, optimizing clinical management for OC patients.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Machine learning
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • TMB-H • PD-L1 overexpression • PD-L1 underexpression • CTLA4 expression
    2ms
    Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. (PubMed, Immunity)
    Moreover, the efficiency of CTLA-4 RNA splicing was increased in tumor-infiltrating Treg cells from patients with colorectal cancer. These findings highlight the immunological relevance of RNA splicing in Treg cells and provide important insights into the environmental mechanism governing CTLA-4 expression in Treg cells.
    Journal • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • FOXP3 (Forkhead Box P3)
    |
    CTLA4 expression • FOXP3 expression
    2ms
    "Expression and prognostic relevance of PD-1, PD-L1 and CTLA-4 immune checkpoints in adrenocortical carcinoma". (PubMed, J Clin Endocrinol Metab)
    The heterogeneous expression of PD1, PD-L1, and CTLA-4 in this large series of well-annotated ACC samples might explain the heterogeneous results of the immunotherapies in advanced ACC. In addition, PD-1 expression is a strong prognostic biomarker that can easily be applied in routine clinical care and histopathological assessment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • PD-1 expression • CTLA4 expression • PD-1 positive • FOXP3 expression
    2ms
    Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bioinformatics analysis. (PubMed, Cancer Rep (Hoboken))
    POSTN is related to pancreatic cancer prognosis, and may influence immune cell infiltration. High expression of POSTN is predicted to correlate with lower sensitivity to immunotherapy with checkpoint inhibitors in pancreatic cancer.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Immune cell
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • POSTN (Periostin)
    |
    CTLA4 expression
    2ms
    Curcumin mediated dendritic cell maturation by modulating cancer associated fibroblasts-derived exosomal miRNA-146a. (PubMed, J Cancer Res Ther)
    Collectively, these findings provide insight into understanding the immunomodulatory role of curcumin in targeting CAFs and modulating TME, thus enhancing antitumor immune response in DC based therapy.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • MIR155 (MicroRNA 155) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • MIR142 (MicroRNA 142) • MIR221 (MicroRNA 221) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • MIR222 (MicroRNA 222)
    |
    miR-155 expression • CTLA4 expression • IL6 expression • miR-221 expression
    2ms
    Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer. (PubMed, Heliyon)
    This study contributes to our understanding of the characteristics of disulfidptosis-related subgroups in BLCA. Disulfidptosis-related signatures can be used to assess the prognosis and immunotherapy of patients with BLCA.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    DIRAS3 (DIRAS Family GTPase 3) • COL5A1 (Collagen Type V Alpha 1 Chain) • NKG7 (Natural Killer Cell Granule Protein 7)
    |
    PD-1 expression • CTLA4 expression
    2ms
    An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. (PubMed, Cell Rep Med)
    We identify an upregulation of CD80 and/or CD86 in tumor tissue of (r/r) diffuse large B cell lymphoma (DLBCL) patients treated with tisagenlecleucel...In addition, immunocompetent mice show an intact CD80-CD19+ B cell population after CAR/CCR T cell treatment. The results reveal the CAR/CCR design as a promising strategy for further translational study.
    Journal • CAR T-Cell Therapy
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
    |
    CTLA4 expression
    |
    Kymriah (tisagenlecleucel-T)
    3ms
    Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Dan Zandberg | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    LAG3 expression • CTLA4 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    3ms
    SLC4A4 moulds the inflammatory tumor microenvironment and predicts therapeutic expectations in colorectal cancer. (PubMed, Curr Med Chem)
    Overall, upregulation of SLC4A4 expression promoted an inflammatory tumor microenvironment in CRC, and RiskScore predicted therapeutic expectancy. SLC4A4 could be a potentially clinically valuable target for CRC therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • SLC4A4 (Solute carrier family 4 member 4)
    |
    PD-L1 expression • CTLA4 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    3ms
    Interleukin-36gamma Mediates the In Vitro Activation of CD8 T Cells from Patients Living with Chronic Human Immunodeficiency Virus-1 Infection. (PubMed, Viral Immunol)
    The addition of 1 ng/mL IL-36gamma also promoted perforin and granzyme B secretion by HIV-1-specific CD8 T cells from patients living with chronic HIV-1 infection. The reduced IL-36gamma levels in patients living with chronic HIV-1 infection might be insufficient for the activation of CD8 T cells, leading to CD8 T cell exhaustion.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • FASLG (Fas ligand) • GZMB (Granzyme B)
    |
    CD8 expression • CTLA4 expression
    3ms
    Relationship between immune checkpoint proteins and neoadjuvant chemotherapy response in breast cancer. (PubMed, Surg Oncol)
    Our study provides preliminary data about the correlation between ICP and clinicopathological status and NAC response in breast cancer, in addition to underlining the requirement for further research to determine their potential as therapeutic targets.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD44 (CD44 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD24 (CD24 Molecule)
    |
    PD-L1 expression • CD44 expression • CTLA4 expression
    3ms
    Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. (PubMed, Cancer Immunol Res)
    We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints.
    Journal • IO biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    CTLA4 expression
    |
    Prolia (denosumab)
    3ms
    Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. (PubMed, Sci Rep)
    Nivolumab increases CTLA-4 expression in the primary tumor, and subsequent nephrectomy increases circulating concentrations of sPD-L1, sPD-L3 (sB7-H3), and s4-1BB. These findings form the basis to consider neoadjuvant immune checkpoint inhibition (ICI) for high-risk ccRCC while the tumor remains in situ and provide the rationale for perioperative strategies of novel ICI combinations.
    Journal • PD(L)-1 Biomarker • IO biomarker • Immunomodulating • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    CTLA4 expression
    |
    Opdivo (nivolumab)
    3ms
    CTLA-4 Checkpoint Inhibition Improves Sepsis Survival in Alcohol-Exposed Mice. (PubMed, Immunohorizons)
    Interrogation of the T cell compartments in these animals following pharmacologic CTLA-4 blockade, as well as following conditional Ctla4 deletion in CD4+ T cells, revealed that CTLA-4 deficiency promoted the activation and proliferation of effector regulatory T cells and the generation of conventional effector memory CD4+ T cells. These data highlight an important role for CTLA-4 in mediating mortality during sepsis in the setting of chronic alcohol exposure and may inform future approaches to develop targeted therapies for this patient population.
    Preclinical • Journal • Checkpoint inhibition • IO biomarker
    |
    CD4 (CD4 Molecule)
    |
    CTLA4 expression
    4ms
    Cyclooxygenase-2 Blockade Is Crucial to Restore Natural Killer Cell Activity before Anti-CTLA-4 Therapy against High-Grade Serous Ovarian Cancer. (PubMed, Cancers (Basel))
    Increased COX-2 expression may hamper the effectivity of immunotherapies that require NK cell effector function. These results provide a foundation for experimental validation and clinical trials investigating combined therapies targeting COX-2 and CTLA-4 in HGSOC.
    Journal • IO biomarker
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    CTLA4 expression • PTGS2 expression
    4ms
    High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. (PubMed, Ther Adv Med Oncol)
    There are two Food and Drug Administration-approved anti-CTLA-4 agents - ipilimumab and tremelimumab - both used together with anti-PD-1/PD-L1 agents. Patients whose tumors had high CTLA-4 and high PD-L1 did best; those with high PD-L1 but non-high CTLA-4 and/or other expression patterns had poorer outcomes for PFS (p = 0.004) and OS (p = 0.009) after immunotherapy. High CTLA-4, especially when combined with high PD-L1 transcript expression, was a significant positive predictive biomarker for better outcomes (PFS and OS) in patients on immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • CTLA4 expression • CTLA4 underexpression
    |
    Yervoy (ipilimumab) • Imjudo (tremelimumab)
    4ms
    Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade? (PubMed, Appl Immunohistochem Mol Morphol)
    This analysis highlights the homogenous molecular and immune profile of eGB and PXA, suggesting the possibility that histologically and molecularly, these two entities represent 2 ends of a continuous spectrum with PXAG3 lying in between. Higher upregulation of PDL1, CTLA-4, and increased tumor infiltrating lymphocytes in these tumors as compared with GB, IDH wt suggests potential candidature for immunotherapy.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ATRX (ATRX Chromatin Remodeler) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • TP53 mutation • BRAF V600E • BRAF V600 • IDH1 mutation • EGFR amplification • CDKN2A deletion • IDH wild-type • CTLA4 expression • IDH1 wild-type + BRAF mutation • PD-L1 expression + CTLA4 expression